Ease-of-use and acceptability of the novel semaglutide 2.4 mg single-dose pen-injector in people with overweight or obesity in the STEP 8 phase III trial.

ABSTRACT:

SUBMITTER: Snitker S 

PROVIDER: S-EPMC9805145 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature